Radiofrequency Ablation of Tumors

Status Completed

Clinical Trial Summary

Background: This prospective study was designed to be the first to evaluate the toxicity of radiofrequency ablation (RFA) in patients with recurrent pediatric solid tumors.

Methods: From 2003 through 2006, we conducted a phase I, IRB-approved study of RFA for recurrent solid tumors. A multidisciplinary cancer management team selected appropriate candidates for the study. Imaging-guided RFA was performed percutaneously. Response was assessed at 3 months. Repeat RFA was performed for some incompletely ablated or new lesions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00705497
Study type	Interventional
Source	St. Jude Children's Research Hospital
Contact
Status	Completed
Phase	Phase 1
Start date	January 2003
Completion date	October 2008

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02933242` - Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases	N/A
Active, not recruiting	`NCT01446744` - Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)	Phase 2
Completed	`NCT00676949` - Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors	Phase 1
Recruiting	`NCT03862911` - Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer	N/A
Recruiting	`NCT05390528` - A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03721341` - Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors	Phase 3
Completed	`NCT01910545` - Phase 1 Study of OTS167 in Patients With Solid Tumors	Phase 1
Completed	`NCT02156388` - Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors	Phase 1